NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC)

MLA

Claudio Bordignon, et al. “NGR-HTNF plus Chemotherapy as First-Line Therapy of Non-Small Cell Lung Cancer (NSCLC).” Journal of Clinical Oncology, vol. 30, May 2012, p. 7581. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8347ed6b73bc8ca4b527f1bb681ad6f1&authtype=sso&custid=ns315887.

APA

Claudio Bordignon, M. Giovannini, Filippo Pietrantonio, Vanesa Gregorc, Nicoletta Zilembo, Gilda Rossoni, Erika Rijavec, Francesco Grossi, Giovanni Citterio, Tommaso De Pas, & Antonio Lambiase. (2012). NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 30, 7581.

Chicago

Claudio Bordignon, M. Giovannini, Filippo Pietrantonio, Vanesa Gregorc, Nicoletta Zilembo, Gilda Rossoni, Erika Rijavec, et al. 2012. “NGR-HTNF plus Chemotherapy as First-Line Therapy of Non-Small Cell Lung Cancer (NSCLC).” Journal of Clinical Oncology 30 (May): 7581. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8347ed6b73bc8ca4b527f1bb681ad6f1&authtype=sso&custid=ns315887.